The global birth tissue products market enjoys a valuation of USD 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 6.6% over the forecasted years. According to a recent study by Future Market Insights, amniotic membrane tissue is leading the market with a share of about 34.2% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | USD 2.3 Billion |
| Market Value 2033 | USD 4.5 Billion |
| CAGR 2023 to 2033 | 6.6% |
| Market Share of Top 5 Countries | 57.2% |
| Key Market Players | Surgenex, LLC.; Organogenesis Inc.; Stryker; Next Biosciences; Skye Biologics Holdings, (LLC); NuVision Biotherapies Ltd.; Merakris Therapeutics; Orthofix Medical Inc.; Amiox medical (Tissue Tech, Bio-tissue); MIMEDX; SURGILOGIX; AlloSource; MTF Biologics; StimLabs. |
The term "birth tissue products market" refers to a quickly expanding sector of the economy that involves utilizing the regeneration capabilities of human birth tissues, such as the placenta and umbilical cord, to create a variety of goods with uses in both medical and cosmetic fields.
These uses include enhancing orthopedic and surgical operations as well as tissue repair and wound healing. Birth tissue products are also known for their capacity to modify the body's immune response, making them an important resource in the creation of cutting-edge treatments for some autoimmune and inflammatory diseases.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 6.6% between 2023 and 2033, owing to the rising prevalence of various ophthalmic conditions.
The global market holds around 18.5% share of the overall global regenerative medicine market with a value of around USD 12.2 Billion, in 2022.
The market for birth tissue products has experienced rapid growth in recent years, and historical trends point to continued growth. Products made from birth tissue are utilized in a variety of medical procedures, such as orthopedic surgery, neurological restoration, ophthalmology, and wound healing.
One key driver of the birth tissue products market has been the rise of regenerative medicine, which uses biological materials to promote tissue growth and repair. With rising research and development in this industry, the demand for birth tissue products is likely to continue to climb.
Regarding the sales prospects, this market still has a lot of space for expansion. There is a chance for businesses to educate and build awareness about these goods because many people and healthcare professionals are still unaware of them and their potential advantages.
Also, when more study is done on the efficacy of these treatments, insurance companies and regulatory bodies may show more support, which might enhance sales. In the end, a variety of factors, including ongoing research and development, increased manufacturing and process efficiencies, and pricing strategies, will determine the sales prognosis for birth tissue products.
Owing to the above-mentioned factors, the global market is expected to grow at a significant pace, and reach a valuation of around USD 4.5 billion during the year 2033.
Increasing interest in the possibilities of birth tissue products has led to an increase in the number of companies producing and marketing these goods. Cooperation between businesses, research centres, and healthcare providers can result in the creation of fresh goods and technology as well as the opening of fresh markets.
Partnerships can also make it easier to introduce new born tissue products by assisting with regulatory and reimbursement challenges. This has made these products more accessible to patients and healthcare professionals.
Birth tissue products also have a lot of potential in regenerative medicine, particularly in the areas of tissue repair and wound healing. The demand for new-born tissue products as a viable therapy option is being driven by an increase in the number of postpartum haemorrhage cases that are being reported as well as other obstetric problems.
Because women need care that is more specialized during the postpartum recovery stage, the surge in cesarean-section births has increased the need for birth tissue products along with the opportunities for the key manufacturers.
Principal Consultant
Birth tissue products must meet a variety of regulatory standards, which may differ from nation to nation, in order to be developed and sold. The market's expansion may be constrained by the time and money required to comply with these rules.
The use of human-born tissue poses moral and legal concerns about things like tissue source, donor permission, and the risk of infectious disease transmission. These worries could reduce the supply of appropriate donor tissue and impair both patients and healthcare professionals' adoption of these items.
The ethical difficulties surrounding the utilization of human tissues present another difficulty. Although placental tissues, which are generally discarded after childbirth, are used to make birth tissue products, there are still concerns about informed consent, donor screening, and the equitable distribution of benefits.
The USA dominates the global region with a total market share of around 32.9% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
The market for newborn tissue products in the United States is expanding due to multiple factors. The growing acceptance of regenerative medicine, which uses tissue-based products to encourage healing and enhance patient outcomes, is a significant contributing element.
There is a growing need for novel treatments as a result of the ageing population and associated growth in chronic diseases like diabetes and osteoarthritis. It has been demonstrated that products made from birth tissue, such as placental membranes, amniotic fluid, and cord blood and tissue, have regenerative and anti-inflammatory qualities that can treat various disorders.
Technological developments and advances in processing and storage have increased the accessibility and availability of these products, driving the market's expansion.
China holds a market share of 9.2% in 2022 in the global birth tissue products market.
The market for birth tissue products in China is expanding at an exponential rhythm. One important element is the growing knowledge of these products' advantages in encouraging tissue regeneration and wound healing among medical practitioners.
The acceptance of newborn tissue products has also been spurred by China's growing need for innovation and fresh, efficient medical technology and treatments.
These goods' affordability and accessibility have contributed to their widespread use in China. The prevalence of chronic diseases and the rising expenses of healthcare have pushed people towards non-invasive treatments like newborn tissue products, making them a popular option in the Chinese medical industry.
Japan has a market share of 5.2%, in the global birth tissue products market in 2022.
Growing knowledge of the advantages of goods made from birth tissue, such as improved wound healing and reduced inflammation the market is growing in Japan. The increasing need for regenerative medicine treatments to address a variety of illnesses and injuries.
Also, technological developments in tissue engineering and production have boosted the effectiveness and safety of goods made from fetal tissue.
The support from the government towards the creation and marketing of items for regenerative medicine, particularly embryonic stem cells, along with the favorable payment practices for the use of maternity tissue products in hospitals.
Chronic illnesses and injuries are more common, necessitating cutting-edge treatments for tissue restoration and wound healing that are boosting the global market in Japan.
India holds a share of around 5.0% in the global market in 2022. The market for birth tissue products is expected to show high growth in the Indian market.
The growing public knowledge of the advantages of these goods is one of the key factors. Products made from birth tissue, such as amniotic fluid, umbilical cord tissue, and placental tissue, have been proven to have healing characteristics that can help with tissue repair and illness therapy.
Increased access to these items is being made possible by India's improvements in healthcare infrastructure, which is further boosting the market for birth tissue products. The market for items made from newborn tissue is anticipated to increase as more hospitals and clinics use these birth tissue products.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The amniotic membrane by tissue holds a 34.2% share in the global birth tissue products market.
The lining of the amniotic sac is the thin but sturdy amniotic membrane. It is a rich source of extracellular matrix proteins, cytokines, and growth factors that can help with tissue regeneration and wound healing.
The amniotic membrane has been employed in a variety of newborn tissue products, including amniotic membrane grafts and products made from umbilical cord tissue, because of its regenerative capabilities. The market has expanded as a result of the rising demand for birth tissue products and the amniotic membrane's distinctive qualities, which have made it a popular choice for use in these goods.
The demand for it has also been fueled by its efficacy in treating a variety of illnesses, including musculoskeletal ailments, skin ulcers, and ocular surface diseases. Hence, the amniotic membrane is crucial to the development of the birth tissue products market.
Wound Care by application has a market share of 32.8% in the global market in 2022.
Gestational tissues, such as the placenta, amniotic membrane, and umbilical cord tissue, are used to make birth tissue products. These tissues' innate healing abilities can speed up the recovery of a variety of wound types, including chronic wounds and surgical wounds. As a result, one of the main applications for newborn tissue products has been wound treatment.
It has been demonstrated that the use of newborn tissue products in wound treatment can promote tissue repair and reduce inflammation, resulting in quicker healing times and better patient outcomes.
As a result of the benefits they provide, both patients and healthcare professionals have raised their demand for these products in the birth tissue products market.
The market is also anticipated to rise as more healthcare professionals adopt cutting-edge solutions to their wound care procedures in response to rising demand, the market for newborn tissue products is predicted to expand significantly over the next several years.
Hospitals hold a market share of 51.9% during the year 2022. Hospitals are essential to the market expansion for birth tissue products.
Hospitals are the main source of the placental and amniotic tissues, which are frequently applied to wounds and used in operations. Due to these products' many advantages, including their ability to improve tissue regeneration, reduce inflammation, and promote healing, demand has been rising.
The proper use of these items is also taught to healthcare professionals by hospitals, and they also carry out research to discover new uses for birth tissue products.
Manufacturers of birth tissue products are focusing on differentiation by expanding into new markets, receiving regulatory permission for more goods, marketing approvals in other regions, and expanding into new geographies.
Along with relationships with globally significant organizations, research, and development. The dynamics of the market have changed due to increasing awareness. In November 2018, Organogenesis Inc.
introduced the Advanced Healing Education Resource Center, a microsite for continuing medical education that includes the most recent conceptual and practical developments in wound healing.
Similarly, recent developments related to companies manufacturing birth tissue products have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2016 to 2022 |
| Forecast data | 2023 to 2033 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia & Pacific; Western Europe; Eastern Europe; Middle East and Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Rest of Latin America, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam, Rest of ASEAN, Australia & New Zealand, Germany, France, Spain, Italy, BENELUX, Nordics, United Kingdom, Poland, Hungary, Romania, Czech Republic, Others, GCC Countries, Kingdom of Saudi Arabia, Türkiye, North Africa, South Africa, Israel. |
| Key Market Segments Covered | Product, Application, End User, and Region |
| Key Companies Profiled | Surgenex, LLC.; Organogenesis, Inc.; Stryker; Next Biosciences; Skye Biological Holdings, (LLC); NuVision Biotherapies Ltd.; Merakris Therapeutics; Orthofix Medical Inc.; Amiox medical (Tissue Tech, Bio-tissue); MIMEDX; SURGILOGIX; AlloSource; MTF Biologics; StimLabs |
| Pricing | Available upon Request |
The market was valued at USD 2.3 billion in 2022.
The market is predicted to expand at a 6.6% CAGR by 2033.
The market is anticipated to be worth USD 4.5 billion by 2033.
The United States held a market share of 32.9% in 2022.
MIMEDX, SURGILOGIX, and AlloSource are the key market players.
Explore Healthcare Insights
View Reports
Birth Tissue Products Market
